Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2020-08-25 Interim / Quarterly Rep…
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
2020年半年度财务报告
Interim / Quarterly Report Classification · 100% confidence The document is titled "2020 年半年度财务报告" which translates to "2020 Half-Year Financial Report." It contains detailed financial statements including consolidated and parent company balance sheets, profit and loss statements, and cash flow statements for the half-year period ending June 30, 2020. The document explicitly states it is a half-year report and includes comprehensive financial data and analysis, not just an announcement or summary. The length is substantial (15,000 characters), indicating it is the full report rather than a brief notice. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). H1 2020
2020-08-25 Chinese
关于与广东省东莞国药集团有限公司签订战略合作协议的公告
Capital/Financing Update Classification · 90% confidence The document is an announcement regarding the signing of a strategic cooperation agreement between 特一药业集团股份有限公司 and 广东省东莞国药集团有限公司. It includes details about the agreement, the parties involved, the purpose, and the potential impact on the company's business. The document explicitly states that the agreement does not have a significant impact on the company's 2020 financial results. There are no financial statements, earnings data, or detailed financial analysis present. The document is a formal announcement of a strategic partnership rather than a financial report or detailed management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is also not a regulatory filing or certification. The content aligns best with a Capital/Financing Update (CAP) as it relates to a strategic business cooperation agreement that could affect the company's operations and market position, which is typical for CAP filings. The document length is short (1979 characters), but it is not merely announcing the publication of a report, so it is not RPA. Therefore, the most appropriate classification is CAP with high confidence.
2020-08-06 Chinese
关于全资子公司拟增加经营范围及修改《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by 特一药业集团股份有限公司 regarding the proposed increase in business scope of its wholly-owned subsidiary and amendments to the company's articles of association. It details changes in the subsidiary's business activities and the related corporate governance document. The document is short (975 characters) and is an announcement of corporate changes rather than a financial report or detailed management discussion. It does not contain financial statements, audit information, or regulatory certifications. It is not a report publication announcement since it contains substantive content about business scope changes. The content fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about corporate governance and business scope changes that do not fit other specific categories.
2020-07-30 Chinese
关于第四届董事会第十三次会议决议的公告
Board/Management Information Classification · 95% confidence The document is an announcement of the resolutions passed at the 13th meeting of the 4th Board of Directors of 特一药业集团股份有限公司. It details the meeting date, attendance, and the approval of a proposal regarding the temporary use of idle raised funds to supplement working capital. There is no financial statement or comprehensive report content, only a summary of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management. The document length is short and it is not a full report or financial disclosure, so it is not an Annual Report or Interim Report. Therefore, the correct classification is MANG with high confidence.
2020-07-24 Chinese
国信证券股份有限公司关于公司使用部分闲置募集资金暂时补充流动资金的核查意见
Audit Report / Information Classification · 95% confidence The document is a verification opinion from Guosen Securities regarding the use of part of idle raised funds by Te Yi Pharmaceutical Group Co., Ltd. to temporarily supplement working capital. It references regulatory rules related to securities issuance and listing, details about the raised funds, and the company's board approval process. The document is a formal verification or audit opinion on the use of funds, not a full financial report or earnings release. It does not contain financial statements or detailed financial data but rather an audit or verification opinion on a specific financial action. Therefore, it fits best under the category of Audit Report / Information (AR). The document length is 2228 characters, which is consistent with a standalone audit or verification report rather than a full annual or interim report. FY 2018
2020-07-24 Chinese
关于使用部分闲置募集资金暂时补充流动资金的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement by 特一药业集团股份有限公司 regarding the use of part of idle raised funds (募集资金) to temporarily supplement working capital. It details the approval by the board, the amount of convertible bonds issued, the use of funds, and assurances that the use does not change the original purpose of the raised funds. It includes opinions from independent directors, the supervisory board, and the sponsoring institution. The document is a formal disclosure about the company's capital usage and financing activities related to the convertible bonds. It is not a full financial report, audit report, or earnings release, but rather an update on financing and capital usage. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is 4156 characters, which is sufficient for a detailed announcement rather than a brief notice or a report publication announcement.
2020-07-24 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.